Cannabinoids, when co-administered with opioids, may enable reduced opioid doses
without loss of analgesic efficacy (ie, an opioid-sparing effect). The aim of this study was to …

For over two decades, cannabis, commonly known as marijuana, has been the most widely
used illicit drug by young people in high-income countries, and has recently become …

The primary psychoactive ingredient in cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), affects
the brain mainly by activating a specific receptor (CB1). CB1 is expressed at high levels in …

In this review we will critically assess the hypothesis that the reinforcing effect of virtually all
drugs of abuse is primarily dependent on activation of the mesolimbic dopamine system …

Cannabinoids—the active components of Cannabis sativa and their derivatives—exert
palliative effects in cancer patients by preventing nausea, vomiting and pain and by …

The active compound in herbal cannabis, Δ9‐tetrahydrocannabinol, exerts all of its known
central effects through the CB1 cannabinoid receptor. Research on cannabinoid …

Cannabinoids and opioids share several pharmacologic properties and may act
synergistically. The potential pharmacokinetics and the safety of the combination in humans …

Background The past two decades have seen an increase in cannabis use due to both
regulatory changes and an interest in potential therapeutic effects of the substance, yet …

Cannabis (marijuana) is not only a frequently abused drug but also has the potential for the
development of useful agents for the treatment of emesis, anorexia and multiple sclerosis. In …

After their discovery, the two known cannabinoid receptors, CB1 and CB2, have been the
focus of research into the cellular signalling mechanisms of cannabinoids. The initial …